- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01207492
Nilotinib bij patiënten met recidiverende of gemetastaseerde gepigmenteerde villonodulaire synovitis/tenosynoviale reusceltumor/diffuse reusceltumor van het type
Een multicenter single-agent fase II-onderzoek naar de werkzaamheid van nilotinib bij patiënten met recidiverende of gemetastaseerde gepigmenteerde villonodulaire synovitis/tenosynoviale reusceltumor/diffuse reusceltumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
- In this research study, each cycle of study drug dosing will last 4 weeks (28 days). During each cycle, participants will take nilotinib by mouth twice daily. During the first cycle, participants will come to the clinic on Days 1 and 8. For Cycles 2-4 and every 3 cycles thereafter, they will come to the clinic on Day 1.
- The following tests and procedures will be performed at specific time points during study treatment: MRI or CT scans; physical examinations; vital signs; blood work; questionnaires and EKG.
- Participants may continue in this research study for as long as they do not have serious side effects or their disease does not get worse.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
California
-
Santa Monica, California, Verenigde Staten, 90403
- Sarcoma Oncology Center
-
Stanford, California, Verenigde Staten, 94305
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111
- Fox Chase Cancer Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically confirmed diagnosis of recurrent PVNS ( or diffuse-type giant cell tumor or tenosynovial giant cell tumor) that is unresectable, metastatic, or for which the patient refuses surgical intervention
- Progressive disease in the last 12 months, as demonstrated by imaging or clinical appearance of new tumors, in the opinion of the treating investigator
- At least one site of measurable disease according to RECIST 1.1 on MRI (or CT scan for metastatic disease)
- Any number or type of prior systemic therapies, with the exception of known or suspected CSF1 receptor inhibitors as outlined in exclusion criteria below
- 18 years of age or older
- Life expectancy greater than 6 months
- ECOG Performance Status of 0, 1 or 2
- Normal organ and marrow function as defined in the protocol
- QTc less than or equal to 450 ms on 12-lead ECG
- Negative urine or serum pregnancy test within days of start of study drug administration for women of childbearing potential.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months following study drug discontinuation
Exclusion Criteria:
- Prior treatment with known or suspected CSF1 receptor inhibitor, including nilotinib, imatinib, sunitinib, or sorafenib, or other approved or investigational tyrosine kinase inhibitors used for treatment of diffuse-type giant cell tumor
- Concurrent treatment with other investigational agents
- Inability to tolerate or contraindication to MRI scanning for participants with localized disease
- Impaired cardiac function
- Current treatment with strong CYP3A4 inhibitors that cannot either be discontinued or switched to a different medication prior to starting study drug
- Current treatment with any medications that have the potential to prolong the QT interval and that cannot either be discontinued or switched to a different medication prior to starting study drug
- Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
- Acute or chronic pancreatic disease
- Acute or chronic liver disease
- Another primary malignant disease requiring systemic treatment or radiation
- History of significant congenital or acquired bleeding disorder unrelated to cancer
- Major surgery within 28 days prior to Day 1 of the study
- Treatment with other investigational agents within 28 days of day 1
- History of non-compliance to medical regimens or inability to grant consent
- Women who are pregnant or breastfeeding
- Other comorbidities that would interfere with study participation or safety in the opinion of the investigator
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Nilotinib
Nilotinib 200 mg taken as 400 mg twice daily, continuously |
Taken orally twice daily |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants With Progression Free Survival
Tijdsspanne: 6 months
|
To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Tumor Response Rate (OR)
Tijdsspanne: 2 years
|
To determine overall tumor response rate [% complete response (CR) + % partial response (PR) by RECIST 1.1]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR. |
2 years
|
|
Clinical Benefit Rate
Tijdsspanne: 6 months
|
To determine the clinical benefit rate [% CR + % PR + % stable disease by RECIST 1.1] at 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
6 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Andrew J. Wagner, MD, PhD, Dana-Farber Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Spierziekten
- Neoplasmata
- Gewrichtsziekten
- Neoplasmata per histologisch type
- Neoplasmata, bindweefsel en zacht weefsel
- Neoplasmata, bindweefsel
- Synovitis
- Tendinopathie
- Gigantische celtumoren
- Gigantische celtumor van peesschede
- Synovitis, Gepigmenteerde Villonodular
- nilotinib
Andere studie-ID-nummers
- 10-179
- YUS23T (Andere identificatie: Novartis)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .